P1vital Limited is a leading clinical research organisation based at Oxford University which coordinates and manages clinical trials for its clients in the area of Central Nervous System (CNS) Experimental Medicine.
Tris Moore has acted for P1vital for more than seven years and has overseen the company’s legal agreements and advised on a number of significant consortiums and collaborations with the major pharmaceutical companies (including Astra Zeneca, GSK, Johnson & Johnson, Lilly, Lundbeck, Merck, Pfizer, Roche, Servier) operating in this area of medicine. These contracts invariably involve regulatory and compliance issues and an IP/IT element due to the creation of results and new IP.
Moore Law also advises P1vital (and its sister products company, P1vital Products Limited) on the complex subcontracting models with its University subcontractors (all clinical trial centres of excellence in their fields of expertise) which underpin its client contracts and in relation to the development of innovative new technologies in support of the studies.
P1vital instructs Moore Law in relation to all significant commercial and IP transactions.
Innovation
P1vital’s innovative experimental medicine studies enable pharmaceutical company clients to make more rapid and effective decisions in the early development of new compounds to treat disabling disorders such as depression and schizophrenia. Moore Law’s role (which from time to time involves us in direct negotiations with Legal Counsel at various pharmaceutical companies and universities) gives us an insight into developments in this area with regard to IP and IT since these trials are increasingly supported by sophisticated software based cognitive and functional MR imaging test batteries developed by the client.
